Abstract
Introduction . Anxiety disorders are among the most common mental disorders in the world, having a significant impact on psychological health and social functioning, including adolescents and young adults. These disorders usually manifest themselves at the age of 10–24 years and lead to serious health problems. Aim. To study the clinical features of anxiety disorders within generalized anxiety disorder (GAD), identify the leading manifestations and additional pantomimic, gestural and behavioral marker symptoms, and evaluate the effectiveness of the anxiolytic maritupirdine (Aviandr®) for the treatment of these conditions. Materials and methods. 142 patients with diagnosed clinical-psychopathological and experimental-psychological methods of GAD were examined. Criteria for inclusion in the study: age 18–24 years, patient’s compliance with the criteria of GAD according to DSM-5. Exclusion criteria: the presence of a clinically relevant somatic or neurological disease, pregnancy or pregnancy planning (in women), taking psychotropic drugs during the month preceding inclusion in the study. The Mini-SMILE test, the Spielberger–Khanin test, and the Beck test were used. Patients were prescribed the anxiolytic Aviandr® 20 mg twice daily for 6 weeks. Results. Among the examined young patients with GAD, 6 groups of GAD manifestations and a number of behavioral markers were identified. A statistically significant decrease in scores was noted in the domain of emotional manifestations, on the scales of mental manifestations and symptoms of stress, in the behavioral domain, in somatic manifestations. The largest relative decrease was found on the Beck scale, with situational anxiety in second place in sensitivity to Aviandr®, personal anxiety, and Mini-MIL scores decreased by more than a third. Conclusion. Aviandr® had a positive effect in reducing the severity of GAD.

This publication has 37 references indexed in Scilit: